Prothena | PRTA - Current Liabilities

Prothena reported $50.15M in Current Liabilities for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 125.63M 9.06M
Agios Pharmaceuticals AGIO:US USD 62.63M 9.03M
ALKERMES ALKS:US USD 497.74M 28.19M
Alnylam Pharmaceuticals ALNY:US USD 767.92M 4.88M
Amgen AMGN:US USD 15.69B 1.36B
Biogen BIIB:US USD 3.27B 653.6M
Biomarin Pharmaceutical BMRN:US USD 588.88M 67.86M
Bluebird Bio BLUE:US USD 126.73M 22.13M
Exelixis EXEL:US USD 324.36M 22.63M
Intercept Pharmaceuticals ICPT:US USD 230.08M 8.49M
Intra Cellular Therapies ITCI:US USD 83.24M 5.83M
IONIS PHARMACEUT IONS:US USD 311.56M 28.11M
Macrogenics MGNX:US USD 48.61M 1.43M
Nektar Therapeutics NKTR:US USD 68.2M 15.78M
Neurocrine Biosciences NBIX:US USD 537.7M 52.6M
Prothena PRTA:US USD 50.15M 451K
Regeneron Pharmaceuticals REGN:US USD 3.85B 969.9M
Seattle Genetics SGEN:US USD 818.4M 92.41M
Ultragenyx Pharmaceutical RARE:US USD 261.21M 33.85M
Vertex Pharmaceuticals VRTX:US USD 2.43B 178.7M
Vital Therapies VTL:US USD 13.08M 1.56M
YTE INCY:US USD 1.16B 150.48M